Adlai Nortye Ltd. (NASDAQ:ANL) Short Interest Update

Adlai Nortye Ltd. (NASDAQ:ANL) saw a large decrease in short interest in October. As of October 31st, there was short interest totalling 3,100 shares, a decrease of 27.9% from the October 15th total of 4,300 shares. Based on an average daily volume of 14,400 shares, the short-interest ratio is currently 0.2 days.

Adlai Nortye Stock Down 0.6 %

Shares of NASDAQ:ANL opened at $3.25 on Friday. Adlai Nortye has a 1 year low of $1.85 and a 1 year high of $17.48. The stock’s fifty day moving average price is $2.18 and its 200-day moving average price is $4.51.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Adlai Nortye in a research note on Monday, November 11th.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.